Previous cancer genetics have revealed several molecular markers in glioma, such as isocitrate dehydrogenase (IDH) mutations, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and 1p19q codeletion, and these molecular markers were correlated with favorable prognosis of glioma patients4. This evidence concerns the gene IDH1 and glioma.